Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: A report from SWOG and MD Anderson

M. Othus, H. Kantarjian, S. Petersdorf, F. Ravandi, J. Godwin, J. Cortes, S. Pierce, H. Erba, S. Faderl, F. R. Appelbaum, E. Estey

Research output: Contribution to journalArticle

Abstract

Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this assumption. We examined TRM rates in 1409 patients treated on SWOG (Southwest Oncology Group) trials and 1942 patients treated at MD Anderson (MDA) from 1991 to 2009. Eighty-eight percent of SWOG patients received '3+7' or regimens of similar intensity while 92% of the MDA patients received ara-C at 1.5-2.0 g/m 2 daily × 3-5 days+other cytotoxic agents. We examined the relationship between time and TRM rates after accounting for other covariates. TRM rates between 1991 and 2009 decreased from 18-3% in SWOG and 16-4% at MDA. Multivariate analyses showed a significant decrease in TRM over time (P=0.001). The decrease in TRM was not limited to younger patients, those with a better performance status or a lower white blood cell count. Though our observations are limited to patients treated with intensive therapy at SWOG institutions and MDA, the decrease in TRM with time emphasizes the problem with historical controls and could be considered when selecting AML induction therapy.

Original languageEnglish (US)
Pages (from-to)289-292
Number of pages4
JournalLeukemia
Volume28
Issue number2
DOIs
StatePublished - Feb 1 2014
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Mortality
Therapeutics
Remission Induction
Cytarabine
Cytotoxins
Leukocyte Count
Multivariate Analysis

Keywords

  • 3+7
  • AML
  • high dose cytarabine
  • induction therapy
  • supportive care
  • treatment-related mortality

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens : A report from SWOG and MD Anderson. / Othus, M.; Kantarjian, H.; Petersdorf, S.; Ravandi, F.; Godwin, J.; Cortes, J.; Pierce, S.; Erba, H.; Faderl, S.; Appelbaum, F. R.; Estey, E.

In: Leukemia, Vol. 28, No. 2, 01.02.2014, p. 289-292.

Research output: Contribution to journalArticle

Othus, M, Kantarjian, H, Petersdorf, S, Ravandi, F, Godwin, J, Cortes, J, Pierce, S, Erba, H, Faderl, S, Appelbaum, FR & Estey, E 2014, 'Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: A report from SWOG and MD Anderson', Leukemia, vol. 28, no. 2, pp. 289-292. https://doi.org/10.1038/leu.2013.176
Othus, M. ; Kantarjian, H. ; Petersdorf, S. ; Ravandi, F. ; Godwin, J. ; Cortes, J. ; Pierce, S. ; Erba, H. ; Faderl, S. ; Appelbaum, F. R. ; Estey, E. / Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens : A report from SWOG and MD Anderson. In: Leukemia. 2014 ; Vol. 28, No. 2. pp. 289-292.
@article{a247933f017f44278b3d0be20180cee0,
title = "Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: A report from SWOG and MD Anderson",
abstract = "Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20{\%} observed 20 years ago. Herein we test this assumption. We examined TRM rates in 1409 patients treated on SWOG (Southwest Oncology Group) trials and 1942 patients treated at MD Anderson (MDA) from 1991 to 2009. Eighty-eight percent of SWOG patients received '3+7' or regimens of similar intensity while 92{\%} of the MDA patients received ara-C at 1.5-2.0 g/m 2 daily × 3-5 days+other cytotoxic agents. We examined the relationship between time and TRM rates after accounting for other covariates. TRM rates between 1991 and 2009 decreased from 18-3{\%} in SWOG and 16-4{\%} at MDA. Multivariate analyses showed a significant decrease in TRM over time (P=0.001). The decrease in TRM was not limited to younger patients, those with a better performance status or a lower white blood cell count. Though our observations are limited to patients treated with intensive therapy at SWOG institutions and MDA, the decrease in TRM with time emphasizes the problem with historical controls and could be considered when selecting AML induction therapy.",
keywords = "3+7, AML, high dose cytarabine, induction therapy, supportive care, treatment-related mortality",
author = "M. Othus and H. Kantarjian and S. Petersdorf and F. Ravandi and J. Godwin and J. Cortes and S. Pierce and H. Erba and S. Faderl and Appelbaum, {F. R.} and E. Estey",
year = "2014",
month = "2",
day = "1",
doi = "10.1038/leu.2013.176",
language = "English (US)",
volume = "28",
pages = "289--292",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens

T2 - A report from SWOG and MD Anderson

AU - Othus, M.

AU - Kantarjian, H.

AU - Petersdorf, S.

AU - Ravandi, F.

AU - Godwin, J.

AU - Cortes, J.

AU - Pierce, S.

AU - Erba, H.

AU - Faderl, S.

AU - Appelbaum, F. R.

AU - Estey, E.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this assumption. We examined TRM rates in 1409 patients treated on SWOG (Southwest Oncology Group) trials and 1942 patients treated at MD Anderson (MDA) from 1991 to 2009. Eighty-eight percent of SWOG patients received '3+7' or regimens of similar intensity while 92% of the MDA patients received ara-C at 1.5-2.0 g/m 2 daily × 3-5 days+other cytotoxic agents. We examined the relationship between time and TRM rates after accounting for other covariates. TRM rates between 1991 and 2009 decreased from 18-3% in SWOG and 16-4% at MDA. Multivariate analyses showed a significant decrease in TRM over time (P=0.001). The decrease in TRM was not limited to younger patients, those with a better performance status or a lower white blood cell count. Though our observations are limited to patients treated with intensive therapy at SWOG institutions and MDA, the decrease in TRM with time emphasizes the problem with historical controls and could be considered when selecting AML induction therapy.

AB - Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this assumption. We examined TRM rates in 1409 patients treated on SWOG (Southwest Oncology Group) trials and 1942 patients treated at MD Anderson (MDA) from 1991 to 2009. Eighty-eight percent of SWOG patients received '3+7' or regimens of similar intensity while 92% of the MDA patients received ara-C at 1.5-2.0 g/m 2 daily × 3-5 days+other cytotoxic agents. We examined the relationship between time and TRM rates after accounting for other covariates. TRM rates between 1991 and 2009 decreased from 18-3% in SWOG and 16-4% at MDA. Multivariate analyses showed a significant decrease in TRM over time (P=0.001). The decrease in TRM was not limited to younger patients, those with a better performance status or a lower white blood cell count. Though our observations are limited to patients treated with intensive therapy at SWOG institutions and MDA, the decrease in TRM with time emphasizes the problem with historical controls and could be considered when selecting AML induction therapy.

KW - 3+7

KW - AML

KW - high dose cytarabine

KW - induction therapy

KW - supportive care

KW - treatment-related mortality

UR - http://www.scopus.com/inward/record.url?scp=84893788771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893788771&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.176

DO - 10.1038/leu.2013.176

M3 - Article

C2 - 23760400

AN - SCOPUS:84893788771

VL - 28

SP - 289

EP - 292

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -